My ePortfolio Register   

Combination immunotherapies and multi-modal treatment

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 18.10.17
Views: 676

Dr Paul Nathan - Mount Vernon Hospital, Northwood, UK

Dr Nathan speaks with ecancer at the ACP immunotherapy workshop about combined immunotherapies and the potential pitfalls of added modalities.

He outlines successes of combined ipilimumab and nivolumab in treating melanoma and kidney cancer, and how toxicities can be managed, noting that patients with more significant adverse reactions simultaneously experience better curative response too.

Dr Nathan highlights the flaws in relying in early data for response and toxicity, and the rights of patients in communication of treatment suitability and availability.

Related videos

follow us

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence